Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Novartis
VM Oncology, LLC
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Azienda USL Reggio Emilia - IRCCS
Cancer Research UK
University of Chicago
National and Kapodistrian University of Athens
Checkpoint Therapeutics, Inc.
Thunder Bay Regional Health Research Institute
Second Affiliated Hospital of Guangzhou Medical University
Memorial Sloan Kettering Cancer Center
Oslo University Hospital
University of Chicago
University of Hull
Candel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
University of Turin, Italy
Quadriga Biosciences, Inc.
A&G Pharmaceutical Inc.
ImmVira Pharma Co. Ltd
M.D. Anderson Cancer Center
University of Calgary
National Institutes of Health Clinical Center (CC)
Shionogi Inc.
University of Maryland, Baltimore
Novartis
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Fox Chase Cancer Center
National Institutes of Health Clinical Center (CC)
Shenzhen BinDeBio Ltd.
National Institutes of Health Clinical Center (CC)
Bayer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Kantonsspital Winterthur KSW
Stanford University
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
CSA Medical, Inc.
Valerio Therapeutics
Valerio Therapeutics